Peritoneal mesothelioma is a cancer of the peritoneum (the lining of the abdominal cavity, approximately 10% of all mesothelioma cases). Currently, surgery and chemotherapy are the standard of care. However, recurrence rates are high. For more information on peritoneal mesothelioma:

Phase II study

In an open label phase II study by Erasmus MC, the safety and efficacy of MesoPher in peritoneal mesothelioma is studied. The title of the study is “Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma”. KWF / Dutch Cancer Society co-finances this study. For more information (Dutch only):